GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scinopharm Taiwan Ltd (TPE:1789) » Definitions » Price-to-Owner-Earnings

Scinopharm Taiwan (TPE:1789) Price-to-Owner-Earnings : 43.00 (As of May. 29, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Scinopharm Taiwan Price-to-Owner-Earnings?

As of today (2025-05-29), Scinopharm Taiwan's share price is NT$17.20. Scinopharm Taiwan's Owner Earnings per Share (TTM) ended in Mar. 2025 was NT$0.40. It's Price-to-Owner-Earnings for today is 43.00.


The historical rank and industry rank for Scinopharm Taiwan's Price-to-Owner-Earnings or its related term are showing as below:

TPE:1789' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 18.19   Med: 48.5   Max: 603.26
Current: 44.51

During the past 13 years, the highest Price-to-Owner-Earnings of Scinopharm Taiwan was 603.26. The lowest was 18.19. And the median was 48.50.


TPE:1789's Price-to-Owner-Earnings is ranked worse than
72.99% of 448 companies
in the Drug Manufacturers industry
Industry Median: 24.98 vs TPE:1789: 44.51

As of today (2025-05-29), Scinopharm Taiwan's share price is NT$17.20. Scinopharm Taiwan's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was NT$0.30. Therefore, Scinopharm Taiwan's PE Ratio (TTM) for today is 57.33.

As of today (2025-05-29), Scinopharm Taiwan's share price is NT$17.20. Scinopharm Taiwan's EPS without NRI for the trailing twelve months (TTM) ended in was NT$0.30. Therefore, Scinopharm Taiwan's PE Ratio without NRI for today is 57.33.

During the past 13 years, Scinopharm Taiwan's highest PE Ratio without NRI was 185.55. The lowest was 41.07. And the median was 63.67.


Scinopharm Taiwan Price-to-Owner-Earnings Historical Data

The historical data trend for Scinopharm Taiwan's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinopharm Taiwan Price-to-Owner-Earnings Chart

Scinopharm Taiwan Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.82 64.87 35.01 573.91 35.22

Scinopharm Taiwan Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 132.78 84.06 105.33 35.22 52.37

Competitive Comparison of Scinopharm Taiwan's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scinopharm Taiwan's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Scinopharm Taiwan's Price-to-Owner-Earnings falls into.


;
;

Scinopharm Taiwan Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Scinopharm Taiwan's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=17.20/0.40
=43.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scinopharm Taiwan  (TPE:1789) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Scinopharm Taiwan Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Scinopharm Taiwan's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Scinopharm Taiwan Business Description

Traded in Other Exchanges
N/A
Address
No. 1, Nan-Ke 8th Road, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144
Scinopharm Taiwan Ltd is a specialty and generic drug manufacturing company. The company is primarily engaged in the manufacturing of medicines, chemicals, biological technology services, active pharmaceutical ingredients, albumin medicines, injections, and new small molecule drugs. Schinopharm also conducts consulting and technical services. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The Company's sales revenue mainly arises from the manufacture and sales of Active Pharmaceutical Ingredient and injection products.

Scinopharm Taiwan Headlines

No Headlines